Oncology Practices
Sell Your Oncology Practice to a Buyer Who Gets the Model
Oncology practices combine complex clinical care with high-value infusion and pharmacy revenue that most buyers don’t fully understand. We help you get a valuation that reflects that complexity, and find a buyer who will protect care continuity for your patients.
Market Snapshot
One of the Most Actively Consolidated Fields in Medicine
Oncology practice sales don’t follow the same playbook as other specialties. A few things make this market distinct.
Oncology Is a Top Consolidation Target
National oncology platforms and private equity–backed networks have been acquiring community oncology practices for over a decade, making this one of the most competitive specialties for well-run practices to sell into.
In-Office Infusion and Pharmacy Drive Value
Buy-and-bill chemotherapy infusion and in-house specialty pharmacy dispensing generate substantial revenue most other specialties don’t have access to, and buyers price this capability heavily.
Value-Based Payment Models Are Reshaping Contracts
Alternative payment models like the Enhancing Oncology Model are shifting how oncology revenue is structured, and buyers want to understand how exposed your practice is to these changes.
Valuation
Three Things That Move Oncology Practice Value
Infusion & Specialty Pharmacy Revenue
In-house chemotherapy infusion and specialty pharmacy dispensing represent a significant, high-volume revenue stream that’s difficult for a buyer to replicate without matching infrastructure.
Payer Mix & Drug Reimbursement Exposure
A healthy payer mix and manageable exposure to buy-and-bill margin pressure gives buyers a clearer, more defensible picture of future revenue.
Subspecialty & Service Line Mix
Medical oncology, radiation oncology, and hematology each carry different reimbursement and referral patterns, which shapes how buyers value and can scale a practice.
Buyer Landscape
Understanding Your Buyer Pool
Because infusion capacity and referral relationships carry real weight in oncology, we help you understand not just what each buyer will pay, but how they tend to run a practice — and its infusion/pharmacy operations — after close.
| Buyer Type | What They're Looking For |
|---|---|
| National oncology networks & PE-backed platforms | backed platforms Multi-site groups with strong infusion and pharmacy revenue, and room to standardize operations across locations. |
| Health systems & hospitals | Practices that strengthen cancer service lines and referral networks within their existing footprint. |
| Individual oncologists | Solo or small practices, often prioritizing patient continuity and clinical culture as much as price. |
Our Process
How We Approach an Oncology Practice Sale
01
Confidential Consultation
Understanding your service lines, ancillary revenue, and what continuity means to you.
02
Specialty Valuation
Accounting for infusion/pharmacy revenue, payer mix, and subspecialty mix.
03
Confidential Marketing
Preparing a confidential executive summary and readying your practice for the market.
04
Buyer Vetting & Offers
Introducing vetted buyers and evaluating how each plans to support your patients and clinical team.
05
Negotiation & Diligence
Navigating diligence, including 340B/drug pricing considerations, pharmacy licensure, and payer contracts.
06
The Handoff
A transition plan built to keep patients, physicians, and referral sources intact.
Proof
Our Track Record
85%
of engagements reach close
80+
combined years of healthcare-specific brokerage experience
95%
of clients land within 10% of expected valuation
FAQ
Common Questions
Will my patients keep seeing the same providers after a sale?
In most transitions, yes — buyers acquiring an oncology practice are typically buying the physician team along with the patient panel, since continuity of care is critical for patients in active treatment. We prioritize buyers who plan to retain your providers, and we build retention terms into the deal structure wherever possible.
How does my in-house infusion and specialty pharmacy affect my valuation?
These capabilities are typically viewed as high-value, high-volume revenue streams that are difficult for a buyer to replicate without matching infrastructure. We help you document infusion volume, drug margins, and pharmacy dispensing revenue clearly so buyers price it as the distinct asset it is.
How do value-based payment models affect what my practice is worth?
Buyers are increasingly attentive to how much of your revenue sits inside alternative payment models versus traditional fee-for-service, since these models shift financial risk. We help you present your participation and performance in these programs clearly, so the valuation reflects your actual risk exposure rather than assumptions.